<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34302866</PMID><DateCompleted><Year>2021</Year><Month>09</Month><Day>06</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-2742</ISSN><JournalIssue CitedMedium="Internet"><Volume>83</Volume><Issue>3</Issue><PubDate><Year>2021</Year><Month>Sep</Month></PubDate></JournalIssue><Title>The Journal of infection</Title><ISOAbbreviation>J Infect</ISOAbbreviation></Journal><ArticleTitle>Crossing the Rubicon: A fine line between waiting and vaccinating adolescents against COVID-19.</ArticleTitle><Pagination><StartPage>294</StartPage><EndPage>297</EndPage><MedlinePgn>294-297</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jinf.2021.07.015</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0163-4453(21)00357-1</ELocationID><Abstract><AbstractText>Several countries with advanced adult COVID-19 immunisation programmes have already started vaccinating adolescents with an mRNA vaccine that recently received emergency use authorisation for 12-15 year-olds. The decision to vaccinate adolescents remains highly divisive among parents, clinicians, politicians and policy makers. There are very few downsides to immunising adolescents with a safe and effective COVID-19 vaccine because that would significantly reduce their risk of COVID-19 and all its complications. Based on current evidence, however, adolescents have a very low risk of severe or fatal COVID-19, even among those with comorbidities, or rare complications such as long COVID or Paediatric Multisystem Inflammatory Syndrome (PIMS-TS), a hyperinflammatory syndrome temporally associated with SARS-CoV-2. Additionally, currently authorised vaccines are very reactogenic and have limited post-marketing population-level safety data in adolescents and young adults, but these are emerging from countries that have forged ahead with vaccinating adolescents. Countries that have yet to make a recommendation can afford to wait until there is sufficient information to make informed decisions on the risk-benefits of vaccinating adolescents with current and future COVID-19 vaccines. Alternatives to two-dose vaccination in adolescents may include a single dose or a reduced dose schedule as is currently being trialled in younger children.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021. Published by Elsevier Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ladhani</LastName><ForeName>Shamez N</ForeName><Initials>SN</Initials><AffiliationInfo><Affiliation>Immunisation and Countermeasures Division, Public Health England, 61 Colindale Avenue, London NW9 5EQ, United Kingdom; Paediatric Infectious Diseases Research Group, St. George's University of London, Cranmer Terrace, London SW17 0RE, United Kingdom. Electronic address: shamez.ladhani@phe.gov.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>07</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Infect</MedlineTA><NlmUniqueID>7908424</NlmUniqueID><ISSNLinking>0163-4453</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C000705967">pediatric multisystem inflammatory disease, COVID-19 related</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="Y">COVID-19 Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018746" MajorTopicYN="N">Systemic Inflammatory Response Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>7</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>7</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>7</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>9</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>7</Month><Day>24</Day><Hour>20</Hour><Minute>11</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>7</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34302866</ArticleId><ArticleId IdType="pmc">PMC8294773</ArticleId><ArticleId IdType="doi">10.1016/j.jinf.2021.07.015</ArticleId><ArticleId IdType="pii">S0163-4453(21)00357-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization (WHO). WHO coronavirus (COVID-19) dashboard. 2021. https://covid19.who.int/(accessed 21 June 2021.</Citation></Reference><Reference><Citation>Docherty A.B., Harrison E.M., Green C.A. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO clinical characterisation protocol: prospective observational cohort study. BMJ. 2020;369:m1985.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7243036</ArticleId><ArticleId IdType="pubmed">32444460</ArticleId></ArticleIdList></Reference><Reference><Citation>Clift A.K., Coupland C.A.C., Keogh R.H. Living risk prediction algorithm (QCOVID) for risk of hospital admission and mortality from coronavirus 19 in adults: national derivation and validation cohort study. BMJ. 2020;371:m3731.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7574532</ArticleId><ArticleId IdType="pubmed">33082154</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization (WHO). COVID-19 vaccine tracker and landscape. 2021. https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines (accessed 22 June 2021.</Citation></Reference><Reference><Citation>Our World in Data. Statistics and research: coronavirus (COVID-19) vaccinations. 2021. https://ourworldindata.org/covid-vaccinations (accessed 21 June 2021.</Citation></Reference><Reference><Citation>Public Helath England (PHE). Guidance: PHE monitoring of the effectiveness of COVID-19 vaccination. Data on the real-world efficacy of the COVID-19 vaccines. 2021. https://www.gov.uk/government/publications/phe-monitoring-of-the-effectiveness-of-covid-19-vaccination (accessed 21 June 2021.</Citation></Reference><Reference><Citation>Wu Z., McGoogan J.M. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese center for disease control and prevention. JAMA. 2020;323(13):1239&#x2013;1242.</Citation><ArticleIdList><ArticleId IdType="pubmed">32091533</ArticleId></ArticleIdList></Reference><Reference><Citation>Molteni E., Sudre C.H., Canas L.S. E. Illness duration and symptom profile in a large cohort of symptomatic UK school-aged children tested for SARS3 CoV-2. MedRxiv. 2021;doi doi: 10.1101/2021.05.05.21256649.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.05.05.21256649</ArticleId><ArticleId IdType="pmc">PMC8443448</ArticleId><ArticleId IdType="pubmed">34358472</ArticleId></ArticleIdList></Reference><Reference><Citation>Ladhani S.N., Amin-Chowdhury Z., Davies H.G. COVID-19 in children: analysis of the first pandemic peak in England. Arch Dis Child. 2020;105(12):1180&#x2013;1185.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7431771</ArticleId><ArticleId IdType="pubmed">32796006</ArticleId></ArticleIdList></Reference><Reference><Citation>Frenck R.W., Klein N.P., Kitchin N. Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 Vaccine in adolescents. N Engl J Med. 2021</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8174030</ArticleId><ArticleId IdType="pubmed">34043894</ArticleId></ArticleIdList></Reference><Reference><Citation>Moderna Inc. Moderna reports first quarter fiscal year 2021 financial results and provides business updates. 06 May 2021. https://investors.modernatx.com/news-releases/news-release-details/moderna-reports-first-quarter-fiscal-year-2021-financial-results (accessed 21 June 2021.</Citation></Reference><Reference><Citation>Pfizer Inc. Coronavirus COVID-19 vaccine updates: our path to developing the pfizer-BioNTech COVID-19 vaccine. 2021. https://www.pfizer.com/science/coronavirus/vaccine/rapid-progress (accessed 21 June 2021.</Citation></Reference><Reference><Citation>Yahoo! News. Countries vaccinating children against COVID-19. 2021. https://news.yahoo.com/countries-vaccinating-children-against-covid-091449825.html (accessed 21 June 2021.</Citation></Reference><Reference><Citation>World Health Organization (WHO). COVID-19 advice for the public: getting vaccinated. 15 June 2021. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccines/advice (accessed 21 June 2021.</Citation></Reference><Reference><Citation>Havers F.P., Whitaker M., Self J.L. Hospitalization of adolescents aged 12&#x2013;17 years with laboratory-confirmed COVID-19 - COVID-NET, 14 states, march 1, 2020-april 24, 2021. MMWR Morb Mortal Wkly Rep. 2021;70(23):851&#x2013;857.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8191866</ArticleId><ArticleId IdType="pubmed">34111061</ArticleId></ArticleIdList></Reference><Reference><Citation>UNICEF. COVID-19 confirmed cases and deaths: age- and sex-disaggregated data. May 2021. https://data.unicef.org/resources/covid-19-confirmed-cases-and-deaths-dashboard/(accessed 21 June 2021.</Citation></Reference><Reference><Citation>Petracek L.S., Suskauer S.J., Vickers R.F. Adolescent and young adult ME/CFS after confirmed or probable COVID-19. Front Med. 2021;8 (Lausanne)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8116546</ArticleId><ArticleId IdType="pubmed">33996867</ArticleId></ArticleIdList></Reference><Reference><Citation>Rando H.M., Bennett T.D., Byrd J.B. medRxiv. 2021. Challenges in defining long COVID: striking differences across literature, electronic health records, and patient-reported information.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.03.20.21253896</ArticleId></ArticleIdList></Reference><Reference><Citation>Flood J., Shingleton J., Bennett E. Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 (PIMS-TS): prospective, national surveillance, UK and Ireland, 2020. The Lancet Regional Health. Europe. 2021 doi: 10.1016/j.lanepe.2021.100075.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanepe.2021.100075</ArticleId><ArticleId IdType="pmc">PMC8132575</ArticleId><ArticleId IdType="pubmed">34027512</ArticleId></ArticleIdList></Reference><Reference><Citation>Payne A.B., Gilani Z., Godfred-Cato S. Incidence of multisystem inflammatory syndrome in children among US persons infected with SARS-CoV-2. JAMA Netw Open. 2021;4(6)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8193431</ArticleId><ArticleId IdType="pubmed">34110391</ArticleId></ArticleIdList></Reference><Reference><Citation>Godfred-Cato S., Bryant B., Leung J. COVID-19-associated multisystem inflammatory syndrome in children - United States, march-July 2020. MMWR Morb Mortal Wkly Rep. 2020;69(32):1074&#x2013;1080.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7440126</ArticleId><ArticleId IdType="pubmed">32790663</ArticleId></ArticleIdList></Reference><Reference><Citation>R.J. Harris, J.A. Hall, A. Zaidi, N.J. NAndrews, J.K. Dunbar, G. Dabrera Effect of Vaccination on Household Transmission of SARS-CoV-2 in England. N Engl J Med 2021 Jun 23;NEJMc2107717. doi: 10.1056/NEJMc2107717.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8262621</ArticleId><ArticleId IdType="pubmed">34161702</ArticleId></ArticleIdList></Reference><Reference><Citation>Paul P., Fabio A. Literature review of HPV vaccine delivery strategies: considerations for school- and non-school based immunization program. Vaccine. 2014;32(3):320&#x2013;326.</Citation><ArticleIdList><ArticleId IdType="pubmed">24295804</ArticleId></ArticleIdList></Reference><Reference><Citation>Schultz N.H., Sorvoll I.H., Michelsen A.E. Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination. N Engl J Med. 2021;384(22):2124&#x2013;2130.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8112568</ArticleId><ArticleId IdType="pubmed">33835768</ArticleId></ArticleIdList></Reference><Reference><Citation>BBC News. Covid: child jabs halted in trial as adult clot link probed. 07 April 2021. https://www.bbc.co.uk/news/health-56656356 (accessed 21 June 2021).</Citation></Reference><Reference><Citation>Hwang J., Lee S.B., Lee S.W. Comparison of vaccine-induced thrombotic events between ChAdOx1 nCoV-19 and Ad26.COV.2.S vaccines. J Autoimmun. 2021;122</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8204660</ArticleId><ArticleId IdType="pubmed">34139631</ArticleId></ArticleIdList></Reference><Reference><Citation>Marshall M., Ferguson I.D., Lewis P. Symptomatic acute myocarditis in seven adolescents following pfizer-BioNTech COVID-19 vaccination. Pediatrics. 2021 doi: 10.1542/peds.2021-052478.</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.2021-052478</ArticleId><ArticleId IdType="pubmed">34088762</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaythorpe K.A.M., Bhatia S., Mangal T. Children's role in the COVID-19 pandemic: a systematic review of early surveillance data on susceptibility, severity, and transmissibility. Sci Rep. 2021;11(1):13903.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8260804</ArticleId><ArticleId IdType="pubmed">34230530</ArticleId></ArticleIdList></Reference><Reference><Citation>McArdle A.J., Vito O., Patel H. Treatment of multisystem inflammatory syndrome in children. N Engl J Med. 2021;385:11&#x2013;22. doi: 10.1056/NEJMoa2102968.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2102968</ArticleId><ArticleId IdType="pmc">PMC8220965</ArticleId><ArticleId IdType="pubmed">34133854</ArticleId></ArticleIdList></Reference><Reference><Citation>Our World in Data. Vaccinations and the impact of COVID-19 &#x2013; our continuously-updated data for Israel. 2021. https://ourworldindata.org/vaccination-israel-impact15 May 2021).</Citation></Reference><Reference><Citation>Milman O., Yelin I., Aharony N., et al. Community-level evidence for SARS-CoV-2 vaccine protection of unvaccinated individuals. Nat Med. 2021 doi: 10.1038/s41591-021-01407-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01407-5</ArticleId><ArticleId IdType="pubmed">34113015</ArticleId></ArticleIdList></Reference><Reference><Citation>Staff T. Times of Israel; 2021. In 2nd School Outbreak, 44 Kids Catch COVID &#x2014; Apparently the Delta Variant. 19 June.</Citation></Reference><Reference><Citation>D. Lewis, Does vaccinating adults stop kids from spreading COVID too? 2021. https://www.nature.com/articles/d41586-021-01549-z (accessed 21 June 2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34113026</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsaban G., Ben-Shimol S. Indirect (herd) protection, following pneumococcal conjugated vaccines introduction: a systematic review of the literature. Vaccine. 2017;35(22):2882&#x2013;2891.</Citation><ArticleIdList><ArticleId IdType="pubmed">28449971</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramsay M.E., Andrews N.J., Trotter C.L., Kaczmarski E.B., Miller E. Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. BMJ. 2003;326(7385):365&#x2013;366.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC148893</ArticleId><ArticleId IdType="pubmed">12586669</ArticleId></ArticleIdList></Reference><Reference><Citation>Mensah A., Sinnathamby M., Zaidi A. SARS-CoV-2 infections in children following the full re-opening of schools and the impact of national lockdown: prospective, national observational cohort surveillance. Engl J Infect. 2021;24 doi: 10.1016/j.jinf.2021.02.022. July-December 2020. February(online ahead of print)</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2021.02.022</ArticleId><ArticleId IdType="pmc">PMC7904496</ArticleId><ArticleId IdType="pubmed">33639175</ArticleId></ArticleIdList></Reference><Reference><Citation>Campbell F., Archer B., Laurenson-Schafer H., Jinnai Y., Konings F., Batra N., Pavlin B., Vandemaele K., Van Kerkhove Maria D., Jombart T., Morgan O., le Polain de W.O. Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at June 2021. Euro Surveill. 2021;26(24) doi: 10.2807/1560-7917.ES.2021.26.24.2100509. pii=2100509.</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2021.26.24.2100509</ArticleId><ArticleId IdType="pmc">PMC8212592</ArticleId><ArticleId IdType="pubmed">34142653</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong B.L.H., Ramsay M.E., Ladhani S.N. Should children be vaccinated against COVID-19 now? Arch Dis Child. 2021 doi: 10.1136/archdischild-2020-321225. archdischild-2020-321225.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/archdischild-2020-321225</ArticleId><ArticleId IdType="pubmed">33402324</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta K., O'Brien W.J., Bellino P. Incidence of SARS-CoV-2 infection in health care workers after a single dose of mRNA-1273 vaccine. JAMA Netw Open. 2021;4(6)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8209555</ArticleId><ArticleId IdType="pubmed">34132795</ArticleId></ArticleIdList></Reference><Reference><Citation>Keech C., Albert G., Cho I. Phase 1-2 Trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. N Engl J Med. 2020;383(24):2320&#x2013;2332.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7494251</ArticleId><ArticleId IdType="pubmed">32877576</ArticleId></ArticleIdList></Reference><Reference><Citation>Heath P.T., Galiza E.P., Baxter D.N. Safety and efficacy of NVX-CoV2373 Covid-19 vaccine. N Engl J Med. 2021 doi: 10.1056/NEJMoa2107659. NEJMoa2107659.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2107659</ArticleId><ArticleId IdType="pmc">PMC8262625</ArticleId><ArticleId IdType="pubmed">34192426</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>